Progress in Research and Development of Glucagon-Like Peptide-1 Analogues
Objective To summarize the progress of research and development(R&D)for glucagon-like peptide-1(GLP-1)analogues.Methods The literature related to GLP-1 analogues in the PubMed and Web of Science from the inception of these databases to February 20,2024 were searched to summarize the R&D progress of GLP-1 analogues from the R&D overview,mono-molecule multi-target GLP-1 receptor agonists(GLP-1RAs),other indications except diabetes mellitus and new trends in R&D.Results and Conclusion GLP-1 analogues has evolved from short-acting to long-acting formulations,from injection to oral medication,and developed to the drugs through multi-target treatment.At present,multi-target GLP-1RAs include dual-target agonists[GLP-1R/glucose-dependent insulinotropic polypeptide receptor,GLP-1R/glucagon receptor(GCGR),GLP-1R/GLP-2R,GLP-1R/amylin 3 receptor(AMY3R),GLP-1R/fibroblast growth factor 21 receptor(FGF-21R)]and triple-target agonists(GLPR/GLP-1R/GCGR,GLP-1R/GCGR/FGF-21R).GLP-1 analogues show great potential in the treatment of diabetes mellitus type 2,overweight,obesity,cardiovascular disease,polycystic ovary syndrome,non-alcoholic steatohepatitis and chronic kidney disease.The dual-target and triple-target GLP-1RAs,which are more effective than single-target GLP-1RAs,have been the focus of R&D in recent years.The recombinant adeno-associated virus vector gene therapy of GLP-1 analogues is a new trend of R&D,its current safety,patients' adherence and solutions are proposed in this study.
glucagon-like peptide-1 analogueglucose-dependent insulinotropic polypeptide receptorglucagon receptordiabetes mellitus type 2
国家科技期刊平台
NSTL
万方数据
维普
